Open AccessQuantifying Conflict of Interest in the Choice of Anti-VEGF Agents
Author(s) -
David J. Browning,
Paul B. Greenberg
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s298575
Subject(s) - ranibizumab , incentive , aflibercept , medicine , reimbursement , drug , bevacizumab , ophthalmology , pharmacology , actuarial science , business , economics , health care , chemotherapy , microeconomics , economic growth
To quantify the economic incentives associated with the choice of anti-VEGF drugs for retinal diseases.